PMID- 34591150
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220321
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 279
IP  - 4
DP  - 2022 Apr
TI  - Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray 
      (GSP301) in the treatment of allergic rhinitis: a systematic review and 
      meta-analysis.
PG  - 1691-1699
LID - 10.1007/s00405-021-07085-w [doi]
AB  - PURPOSE: GSP301 is a fixed-dose combination of olopatadine hydrochloride 
      (antihistamine) and mometasone furoate (corticosteroid). This meta-analysis aims 
      to evaluate the efficacy and safety of GSP301 in the treatment of allergic 
      rhinitis. METHODS: A systematic review and meta-analysis were conducted. The data 
      were collected from PubMed, Cochrane Central Register of Controlled Trials and 
      Embase databases till June 2021. In patients with AR, short-term (2/6 weeks) and 
      long-term (52 weeks) effects of GSP301 were assessed. Average morning and evening 
      12-h reflective total nasal symptom score (rTNSS), instantaneous total nasal 
      symptom score (iTNSS), reflective total ocular symptom score (rTOSS), 
      instantaneous total ocular symptom score(iTOSS), Physician-assessed nasal symptom 
      score (PNSS), rhinoconjunctivitis quality of life (RQLQ), rhinitis control 
      assessment test (RCAT) and adverse events (AEs) were measured. RESULTS: Five 
      randomized controlled trials were included. GSP301 showed greatly improvement in 
      rTNSS (MD = - 0.99; [95% CI - 1.19 to - 0.79]; P < 0.01; I(2) = 0), iTNSS (MD = - 
      1.05; [95% CI - 1.44 to - 0.67]; P < 0.01; I(2) > 50%), rTOSS (MD = - 0.50; [95% 
      CI - 0.72 to - 0.29]; P < 0.01; I(2) = 0), iTOSS (MD = - 0.64; [95% CI - 1.02 to 
      - 0.26]; P < 0.01; I(2) > 50%), PNSS (MD = - 1.01; [95% CI - 1.32 to - 0.69]; 
      P < 0.01; I(2) = 22.13%), RQLQ (MD = - 0.43; [95% CI - 0.57 to - 0.30]; P < 0.01; 
      I(2) = 0%) and RCAT (MD = 1.94; [95% CI 1.43-2.45]; P < 0.01; I(2) = 0%) in the 
      short term. No statistical difference was observed in the outcome of long-term 
      PNSS, RQLQ and RCAT. CONCLUSION: GSP301 is a safe and well-tolerated medication. 
      It showed short-term benefits for seasonal and perennial AR, but may not help to 
      improve patients' quality of life and rhinitis control in the long run.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Chen, Ru
AU  - Chen R
AD  - Bengbu Medical College Graduate Department, Bengbu, China.
AD  - Department of Otolaryngology, Affiliated Hospital of Jiaxing University, No. 1882 
      Zhonghuan South Road, Jiaxing, China.
FAU - Zheng, Dandan
AU  - Zheng D
AD  - Bengbu Medical College Graduate Department, Bengbu, China.
FAU - Zhang, Yajun
AU  - Zhang Y
AD  - Department of Otolaryngology, Affiliated Hospital of Jiaxing University, No. 1882 
      Zhonghuan South Road, Jiaxing, China.
FAU - Sima, Guoqi
AU  - Sima G
AUID- ORCID: 0000-0001-9218-9792
AD  - Bengbu Medical College Graduate Department, Bengbu, China. smgq73@163.com.
AD  - Department of Otolaryngology, Affiliated Hospital of Jiaxing University, No. 1882 
      Zhonghuan South Road, Jiaxing, China. smgq73@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210930
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Nasal Sprays)
RN  - 04201GDN4R (Mometasone Furoate)
RN  - 2XG66W44KF (Olopatadine Hydrochloride)
SB  - IM
MH  - Administration, Intranasal
MH  - *Anti-Allergic Agents/therapeutic use
MH  - Double-Blind Method
MH  - Humans
MH  - Mometasone Furoate/therapeutic use
MH  - Nasal Sprays
MH  - Olopatadine Hydrochloride/adverse effects
MH  - Quality of Life
MH  - *Rhinitis, Allergic/drug therapy
MH  - *Rhinitis, Allergic, Seasonal/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - GSP301
OT  - Mometasone
OT  - Olopatadine
EDAT- 2021/10/01 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/09/30 12:26
PHST- 2021/07/27 00:00 [received]
PHST- 2021/09/10 00:00 [accepted]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/09/30 12:26 [entrez]
AID - 10.1007/s00405-021-07085-w [pii]
AID - 10.1007/s00405-021-07085-w [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2022 Apr;279(4):1691-1699. doi: 
      10.1007/s00405-021-07085-w. Epub 2021 Sep 30.